What it is
Adipotide, also written FTPP, is a synthetic chimeric peptidomimetic that joins a homing sequence targeting blood vessels of white adipose tissue to a segment that triggers cell death in that vasculature.
In this article
What it is
Adipotide, also written FTPP, is a synthetic chimeric peptidomimetic. It joins a homing sequence that binds prohibitin on the blood vessels supplying white adipose tissue to a proapoptotic segment that triggers cell death in that vasculature. The stated research premise is to reduce a fat depot by cutting its blood supply rather than by acting on appetite or metabolic rate.
Research context
Grouped under weight and metabolic research. The most-cited work is a 2011 study in rhesus macaques, where treated animals lost roughly 10.6% of body weight over 28 days. That same study reported dose-dependent changes in kidney tubular function.
A Phase I trial (NCT01262664) was terminated because of dose-limiting nephrotoxicity, and development was discontinued in 2019. Any description of adipotide as a fat-loss agent should carry that outcome with it — the programme stopped for safety, not for lack of interest.
Status
- Regulatory status: Not FDA-approved for human use. No approved indication; clinical development discontinued in 2019.
- Sport status: Not specifically listed by name on the WADA Prohibited List. Note that WADA S0 covers substances with no current regulatory approval for human therapeutic use.
Reconstitution and handling
Reconstitution follows the standard math: concentration equals the milligrams in the vial divided by the millilitres of bacteriostatic water added. There is no single correct concentration — it depends on solubility and how large a draw is wanted. If a mix does not go fully clear, add more water. The reconstitution calculator shows concentration, draw size and portions per vial for any volume.
Refrigerate reconstituted vials at 2–8 °C, keep them out of light, wipe stoppers with alcohol before each puncture, and label with the mix date. Discard anything cloudy, discoloured, or with floaters.
Status in sport
Adipotide is not named on the WADA Prohibited List. However, category S0 (unapproved substances) covers any pharmacological substance with no current approval for human therapeutic use, which is the situation adipotide is in. Verify against the current year’s list.
Related reading
Reminder: research and educational reference only. Preppin Peppers sells hardware and materials, not peptides. Not medical, dosing, or health advice, not evaluated by the FDA, and not intended for human or animal use.
Frequently asked questions
Is Adipotide FDA-approved?
No. It has no approved indication, and clinical development was discontinued in 2019 after a Phase I trial was terminated for dose-limiting kidney toxicity.
What does Adipotide target?
It binds prohibitin on the vasculature supplying white adipose tissue and triggers cell death there, reducing the blood supply to that tissue. It does not act on appetite signalling the way incretin compounds do.
Why did development stop?
The Phase I trial NCT01262664 was terminated because of dose-limiting nephrotoxicity. Kidney tubular changes had already been observed, dose-dependently, in the 2011 primate study.
What the research community gets wrong about Adipotide
- The primate weight-loss figure is not the whole result. The same study that reported roughly 10.6% body-weight loss over 28 days also reported dose-dependent renal tubular changes. Citing one without the other misrepresents the finding.
- Vendor labels are not assays. Identity and purity come from a certificate of analysis on the batch in front of you, not from the name printed on a vial.
- A reconstituted vial does not stay good forever. Compounds in solution break down over time, and rough handling (shaking hard enough to foam) can damage them. Note the reconstitution date and store as your protocol calls for.
Sources
- Barnhart KF, et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med, 2011
- ClinicalTrials.gov NCT01262664 — Phase I study of Adipotide (terminated)
- Bacteriostatic Water for Injection, USP — FDA/DailyMed label (0.9% benzyl alcohol)
- Sigma-Aldrich (Merck) — Handling and Storage Guidelines for Peptides and Proteins
✔ Reviewed by Bryan Le, PharmD, RPh
Bryan is a licensed pharmacist (Doctor of Pharmacy, Registered Pharmacist). Reconstituting lyophilized preparations is core pharmacy practice, so he reviews The Lab’s content for technical accuracy and to keep it within a research-and-education scope, with no medical or dosing advice. View profile on LinkedIn.
